W

Researcher Profile

William R Spreen

4

Publications

844

Citations

10

Co-Authors

3

Active Years

Publications

Open Access Journal Article Clinical Infectious Diseases Jun 21, 2023

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Chloe Orkin · Jonathan M Schapiro · Carlo F Perno · Daniel R Kuritzkes +19 more

10.1093/cid/ciad370 108 citations

Open Access Journal Article Clinical Infectious Diseases Jan 20, 2023

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T Overton · Gary Richmond · Giuliano Rizzardini · Anders Thalme +21 more

10.1093/cid/ciad020 107 citations

Journal Article The Lancet Sep 01, 2017

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

David A Margolis · Juan Gonzalez-Garcia · Hans-Jürgen Stellbrink · Joseph J Eron +20 more

10.1016/s0140-6736(17)31917-7 443 citations

Journal Article The Lancet Infectious Diseases Oct 01, 2015

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

David A Margolis · Cynthia C Brinson · Graham H R Smith · Jerome de Vente +12 more

10.1016/s1473-3099(15)00152-8 186 citations

Publication Timeline

2023

2

2017

1

2015

1

Frequent Co-Authors

Kimberly Y Smith

Sandy K Griffith

Kati Vandermeulen

Veerle Van Eygen

David A Margolis

Peter E Williams